Orient (605116.SH) will pay 0.22 yuan per share in 2023. The stock registration date is June 5

Orient (605116.SH) issued an announcement. The company will implement the 2023 annual equity distribution, and each share will be distributed to discover...

Zhitong FinanceMay 29 17:33

Express News | Orient: Synthetic biology has been applied to products such as simeglutide and remegipam

BreakingsMay 8 15:36

Orient (605116): Performance showed rapid growth, and didroprogesterone preparations gradually contributed to the increase in core performance

Incident Overview (1) Company Announcement 2023 Annual Report: 23 Achieved annual revenue of 1,263 billion yuan, a year-on-year increase of 25.24%, and realized net profit to mother of 289 million yuan, an increase of 37.19% year-on-year, and realized deductions

華西證券May 5 00:00

Orient (605116): Integrated API formulation breaks through production capacity release to ensure future growth

Core view The company's revenue and profit continued to grow rapidly in 2023, and 24Q1 profit growth exceeded expectations. In terms of APIs, cardiovascular and anti-tumor drugs are developing rapidly, and within 23 years, the company has achieved a breakthrough in the integration of API formulations.

中信建投證券May 5 00:00

Orient (605116): Barrier varieties continue to increase in volume profits

Key investment performance: 2023&2024Q1 profit growth was high, and the company's revenue in 2023 was 1,263 million yuan (YOY 25.24%), and net profit to mother was 289 million yuan (YOY 37.19%).

浙商證券May 1 00:00

Orient (605116): The API business is growing steadily, and didroprogesterone tablets open a new chapter in formulation

Event: On April 29, 2024, the company released its 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved operating income of 1,263 billion yuan, a year-on-year increase of 25.24%, and net profit to mother 2.

銀河證券Apr 30 00:00